Establishing a Unified COVID-19 “Immunome”: Integrating Coronavirus Pathogenesis and Host Immunopathology
Year: 2020
Type: article
Abstract: sponsorship: We acknowledge internal funding by KU Leuven (Belgium), UZ Leuven (Belgium) and VIB (Belgium) for this study, as well as the massive effort of all patients, researchers (PhDs/postdocs/technicians), clinicians and nurses involved in COntAGIous clinical-trial consortium (NCT04327570), currently aiming to establish a COVID-19 immunome. EW is supported by Stichting tegen Kanker (Mandate for basic & clinical oncology research). JG holds a postdoctoral research fellowship granted by the University Hospitals Leuven. AG is supported by Research Foundation Flanders (FWO) (G0B4620N; EOS grant: 30837538), KU Leuven (C14/19/098; POR/16/040) and Kom op Tegen Kanker (KOTK/2018/11509/1). (KU Leuven (Belgium), UZ Leuven (Belgium), VIB (Belgium), Stichting tegen Kanker (Mandate for basic & clinical oncology research), University Hospitals Leuven, Research Foundation Flanders (FWO)|G0B4620N, Research Foundation Flanders (FWO) (EOS grant)|30837538, KU Leuven|C14/19/098, KU Leuven|POR/16/040, Kom op Tegen Kanker|KOTK/2018/11509/1)
Source: Frontiers in Immunology
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: G153099885, G1958324674, G2402176342, G3491932767, Deciphering and targeting novel immune-checkpoints engaged by dying cancer cells, to improve anti-cancer immunotherapy, G3670944424, G4455969360, G4508145075, G4982702617, G5653589078, G5658374170, Studying the impact of programmed cancer cell death pathways on Type I interferons-based immunotherapy, G6108111472, G6995216973, G703244163, G8282937928
OpenAlex ID: W3037685395
